WEBULL
News
BIIB
189.57
+0.30%
0.58
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Biogen (BIIB) and Quest Diagnostics (DGX)
TipRanks · 11h ago
Top Biotech Executive Makes Significant Insider Move at Biogen
TipRanks · 13h ago
Biogen Is Maintained at Neutral by Wedbush
Dow Jones · 1d ago
Biogen Price Target Raised to $187.00/Share From $178.00 by Wedbush
Dow Jones · 1d ago
Wedbush Maintains Neutral on Biogen, Raises Price Target to $187
Benzinga · 1d ago
Biogen price target raised to $187 from $178 at Wedbush
TipRanks · 1d ago
BIOGEN <BIIB.O>: WEDBUSH RAISES TARGET PRICE TO $187 FROM $178
Reuters · 1d ago
Biogen Refocuses On High-Need Neurology As New Drugs Reach Inflection Point
Simply Wall St · 1d ago
Biogen Is Maintained at Buy by Canaccord Genuity
Dow Jones · 1d ago
Biogen Price Target Raised to $230.00/Share From $220.00 by Canaccord Genuity
Dow Jones · 1d ago
Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $230
Benzinga · 1d ago
Biogen Is Maintained at Market Perform by BMO Capital
Dow Jones · 1d ago
BMO Capital Maintains Market Perform on Biogen, Raises Price Target to $196
Benzinga · 1d ago
Biogen Is Maintained at Buy by TD Cowen
Dow Jones · 1d ago
TD Cowen Maintains Buy on Biogen, Raises Price Target to $215
Benzinga · 1d ago
Biogen Is Maintained at Neutral by Citigroup
Dow Jones · 1d ago
Biogen Price Target Raised to $215.00/Share From $185.00 by Citigroup
Dow Jones · 1d ago
Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification'
Benzinga · 2d ago
Biogen Is Maintained at Outperform by RBC Capital
Dow Jones · 2d ago
Biogen Price Target Raised to $233.00/Share From $217.00 by RBC Capital
Dow Jones · 2d ago
More
Webull provides a variety of real-time BIIB stock news. You can receive the latest news about Biogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).